Código QR (código de barras bidimensional)

Efficacy and Safety for the Use of Half-Dosed Pegylated Granulocyte Colony-Stimulating Factors in Preventing Febrile Neutropenia During Chemotherapy in Patients With Malignant Tumors: A Multicenter, Open-Labeled, Single-Arm Phase 2 Trial

BackgroundProphylactic granulocyte-colony stimulating factor (G-CSF) has been shown to effectively prevent febrile neutropenia (FN) and grade 3/4 neutropenia during myelosuppressive treatment. The present study reports the clinical efficacy and safety of the prophylactic use of G-CSF with a half dos...

ver descrição completa

Na minha lista:
Principais autores: Qi Mei, Xiaoyu Li, Runkun Wang, Kai Qin, Yi Cheng, Weiting Cheng, Youhong Dong, Zhen He, Jun Li, Ming Li, Xi Tang, Xudong Wang, Xuxuan Xiao, Bin Yang, Yajuan Zhou, Rui Wang, Qiao Huang, Guangyuan Hu, Jian Li
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2022-04-01
coleção:Frontiers in Oncology
Assuntos:
febrile neutropenia
chemotherapy
phase 2 trial
half dose of PEG-rhG-CSF
adverse effect
multiple cancers
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2022.820324/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados